Unmixed Monoclonal Antibody Bevacizumab from Canada
Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) for use in cancer therapy. It falls under HTS 3002.13.00 as an unmixed immunological product, not put up in measured doses or retail packings, consistent with chapter note definitions for immunological products like monoclonal antibodies directly involved in immunological regulation. Supplied in bulk liquid form for pharmaceutical compounding.
Duty Rate — Canada → United States
100%
Rate breakdown
9903.04.60100%Except as provided in heading 9903.04.61, patented pharmaceutical articles as provided for in subdivisions (c) and (d) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
Import Tips
• Verify FDA biologics license and provide certificates of analysis for purity and biotech origin; ensure cold chain documentation to maintain stability; avoid retail packaging to prevent reclassification under 3002.15